[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Giordano S, Pampinella D, Alù M, Agostara B, Romano A: [EBV reactivation in a patient undergoing chemotherapy for invasive thymoma]. Infez Med; 2007 Sep;15(3):195-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EBV reactivation in a patient undergoing chemotherapy for invasive thymoma].
  • [Transliterated title] Riattivazione di EBV in un paziente sottoposto a chemioterapia per metastasi da timoma misto invasivo.
  • Over the last few years evidence has emerged to indicate the involvement of herpes viruses in several infectious complications observed in patients undergoing antiblastic chemotherapy.
  • We present a case of bilateral parotiditis due to EBV reactivation in a patient who had received chemotherapy because of an invasive thymoma.
  • In October 2006, a 53-year-old man with pulmonary and pleural metastases owing to an invasive thymoma, was started on chemotherapy with cisplatin, adriamycin and cyclophosphamide.
  • In January 2007, after consultation with an infectious disease specialist, the patient was admitted to the oncology department because of bilateral swelling of the parotid glands which was most likely of infectious or mycotic origin and attributed to immunosuppression by chemotherapy (the last cycle was completed on 28th December 2006).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Epstein-Barr Virus Infections / complications. Parotitis / virology. Thymoma / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940405.001).
  • [ISSN] 1124-9390
  • [Journal-full-title] Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive
  • [ISO-abbreviation] Infez Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Grohn P, Uttamchandani A, Al-Haider Z, Adams B: Successful management of a widespread osteosarcoma. A case report. Med Princ Pract; 2004 Jan-Feb;13(1):54-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: To report the case of a 23-year-old woman with widespread osteosarcoma including skeletal, pulmonary and pleural metastases, who had a remarkable response to combined chemo- and radiotherapy.
  • CT scan of the chest showed multiple pulmonary metastases and a huge left pleural effusion.
  • Bone scan with technetium-99m hydroxymethylene diphosphonate showed intense uptake of the radiopharmaceutical in the distal right femur, generalized deposits throughout the skeleton and in the right hemithorax corresponding to the lung findings.
  • Histopathology from the femoral tumor showed osteosarcoma.
  • Treatment was started with radiotherapy to the cervical spine followed immediately by a combination chemotherapy with ifosfamide, cisplatin, etoposide and mesna rescue.
  • Eleven cycles of chemotherapy were given with a remarkable response.
  • CONCLUSION: The patient was successfully treated with a combination of radio- and chemotherapy.
  • The disease remained stable 24 months after the discontinuation of the treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Osteosarcoma / drug therapy. Osteosarcoma / radiotherapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Remission Induction

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14657622.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Yoshino S, Okabe T: Advanced renal cell carcinoma in which a combination of IFN-alpha and meloxicam was thought to be effective. Int J Urol; 2003 Jan;10(1):52-5
Hazardous Substances Data Bank. Meloxicam .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 83-year-old man with left renal cell carcinoma (RCC; pT4N0M0) was treated with postoperative combined subcutaneous injection therapy of alpha interferon (IFN-alpha) and IFN gamma-1a (IFN-gamma-1a).
  • Metastasis to the pleura occurred 3 months after surgery.
  • The metastatic lesion grew while the treatment was changed to intramuscular injection of IFN-alpha-2b due to the presence of severe general malaise, which seemed to be caused by IFN-alpha and IFN-gamma therapy.
  • As melosalgia associated with sciatica was also severe, treatment with meloxicam, which is known as a potent cyclooxigenase-2 inhibitor among commercially available non-steroidal anti-inflammatory drugs, was combined, resulting in significant improvement in activity of daily life, 43.2% decrease in the size of the pleural metastasis and complete regression of retroperitoneal residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Interferon-alpha / therapeutic use. Kidney Neoplasms / drug therapy. Thiazines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Fatigue / chemically induced. Fatigue / drug therapy. Humans. Interferon-gamma / therapeutic use. Isoenzymes / antagonists & inhibitors. Male. Nephrectomy. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Recombinant Proteins. Sciatica / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12534928.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Interferon-alpha; 0 / Isoenzymes; 0 / Recombinant Proteins; 0 / Thiazines; 0 / Thiazoles; 71125-38-7 / meloxicam; 82115-62-6 / Interferon-gamma; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


Advertisement
4. Robain M, Pierga JY, Jouve M, Asselain B, Diéras V, Beuzeboc P, Palangié T, Dorval T, Extra JM, Scholl S, Pouillart P: Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer; 2000 Dec;36(18):2301-12
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer.
  • Since response to chemotherapy is a major determinant of survival in metastatic breast cancer, the purpose of our study was to analyse the predictive factors of response.
  • 1426 patients enrolled into eight consecutive randomised trials of anthracycline-based first-line chemotherapy in metastatic breast cancer, between 1977 and 1992, were analysed.
  • The objective response rate (ORR) to chemotherapy in the total population was 63.6% (95% confidence interval (CI): 61.5-67.7).
  • Multivariate analysis defined adjuvant chemotherapy, lactate dehydrogenase (LDH), Karnofsky index (KI), and pleural and lung metastases to be the five main variables correlated with ORR.
  • A predictive score was calculated using the coefficient of these five variables, The score was established as follows: -1.32+0.54 (if prior adjuvant chemotherapy) +0.80 (low KI) +0.75 (raised LDH) +0.49 (lung metastases) +0.51 (pleural metastases).
  • This score can be used to predict objective response rates to first-line anthracycline-based chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prospective Studies. Randomized Controlled Trials as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094303.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Shitara K, Munakata M, Ishiguro A, Kudo T, Okada R, Tomioka R, Mitobe S, Yokoyama S, Sakata Y: [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1497-1500
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
  • BACKGROUND: Colonic perforation due to colitis is a known and reported side effect of chemotherapy.
  • CASE REPORT: A 53-year-old woman was treated with combination chemotherapy of irinotecan plus cisplatin for a recurrent ovarian clear cell adenocarcinoma.
  • After two cycles of treatment, she developed a colonic perforation.
  • Emergency laparotomy was not performed because of poor performance status with multiple lung metastases, pleural effusion and pericardial effusion.
  • Oral intake could be restarted for a while, but she died from tumor progression one and a half months after the diagnosis of perforation.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Diseases / etiology. Intestinal Perforation / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colonoscopy. Drainage. Drug Administration Schedule. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033246.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Perrot E, Davy N, Poubeau P, Arvin-Berod C: [Chemotherapy with paclitaxel for lung metastases of cystic adenoid carcinoma. A case report and review of the literature]. Rev Pneumol Clin; 2003 Dec;59(6):371-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with paclitaxel for lung metastases of cystic adenoid carcinoma. A case report and review of the literature].
  • [Transliterated title] Chimiothérapie par paclitaxel dans les métastases pulmonaires des carcinomes adénoïdes kystiques. A propos d'un cas et revue de la littérature.
  • Cystic adenoid carcinoma, which generally develops in the salivary glands, is a rare primary lung tumor.
  • Locoregional treatment classically associates surgery and radiotherapy.
  • Approximately half of the patients develop metastases; appropriate treatment with chemotherapy remains to be defined.
  • We report the case of a woman who developed lung and pleural metastases of a right submaxillary cystic adenoid carcinoma.
  • Chemotherapy with paclitaxel provided partial tumor response after three cycles.
  • We present a review of the literature on chemotherapy for cystic adenoid carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Paclitaxel / therapeutic use. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14745344.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Mizuta N, Sakaguchi K, Mizuta M, Ichida M, Ohashi M, Umeda Y, Nishiyama A, Matsumoto M, Fujiwara I: [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1317-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
  • We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid.
  • We administered 4 courses of tri-weekly CE (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2) and 12 courses of weekly paclitaxel (80 mg/m2) as adjuvant chemotherapy.
  • However, combination therapy with S-1 and zoledronic acid was started because of the development of bone and pleura metastases.
  • After 3 cycles of treatment, the patient's tumor marker levels had decreased to normal values, and both the bone and pleura metastases had disappeared.
  • A long-term complete response was obtained as a result of this combination therapy.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Oxonic Acid / therapeutic use. Pleural Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Drug Combinations. Humans. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647717.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Drug Combinations; 0 / Imidazoles; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


8. Traen K, Logghe H, Maertens J, Mattelaere C, Moerman P, Vergote I: Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):998-1003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy.
  • The patient recurred and was successfully treated with high-dose chemotherapy and peripheral blood cell transplantation.
  • Because of their location, an early diagnosis of vulvar EST should be possible.
  • Resection of the lesion by using a modified radical vulvectomy followed by cisplatin-based chemotherapy seems the best treatment for these tumors today.
  • Our patient was initially treated with the help of local surgery and adjuvant chemotherapy consisting of three courses of etoposide and cisplatin.
  • Sixteen months after the first diagnosis, pleural and lung metastases were diagnosed.
  • Second-line chemotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell support was administered after resection of the lung metastases and biopsy of the pleural metastases.
  • There is no evidence of disease 40 months after the diagnosis of the lung and pleural metastases, and 56 months after the primary diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Neoplasm Recurrence, Local / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Neoplasm Metastasis. Peripheral Blood Stem Cell Transplantation. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361214.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; TIP regimen
  •  go-up   go-down


9. de Bree E, van Ruth S, Baas P, Rutgers EJ, van Zandwijk N, Witkamp AJ, Zoetmulder FA: Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest; 2002 Feb;121(2):480-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
  • STUDY OBJECTIVES: No established curative treatment is available for pleural thymoma metastases and malignant pleural mesothelioma (MPM).
  • Recently, peritoneal malignancies have been treated by cytoreductive surgery and intraoperative hyperthermic intracavitary perfusion chemotherapy (HIPEC).
  • We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity.
  • DESIGN: Patients with pleural thymoma metastases or early-stage MPM were enrolled in a feasibility study.
  • SETTING: The Netherlands Cancer Institute.
  • PATIENTS: Three patients with pleural thymoma metastases and 11 patients with pleural mesothelioma were treated.
  • INTERVENTIONS: Cytoreductive surgery and intraoperative hyperthermic intrathoracic perfusion chemotherapy (HITHOC) with cisplatin and adriamycin were performed.
  • Severe chemotherapy-related complications were not observed.
  • A solitary mediastinal and a contralateral pleural thymoma recurrence were successfully treated by radiotherapy and a contralateral HITHOC procedure.
  • Two mesothelioma patients died of contralateral pleural and peritoneal recurrent disease, while one patient is alive with locoregional recurrence.
  • CONCLUSIONS: Cytoreductive surgery and HITHOC with cisplatin and adriamycin is feasible in patients with pleural thymoma metastases and early-stage MPM, and is associated with acceptable morbidity rates.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / secondary. Pleural Neoplasms / therapy. Thymoma / secondary. Thymoma / therapy. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate


10. Kusama M, Kaise H, Nakayama S, Ota D, Katsumata K, Aoki T: [A case of aged advanced breast cancer with multiple lung and pleural metastases responding to exemestane monotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1551-4
Hazardous Substances Data Bank. EXEMESTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of aged advanced breast cancer with multiple lung and pleural metastases responding to exemestane monotherapy].
  • A 76-year-old woman was diagnosed with advanced breast cancer with bilateral multiple lung and pleural metastases in March 2003.
  • However, she refused intensive chemotherapy and chose a hormonal monotherapy with exemestane instead.
  • The patient then did not return to our department for about one year, during which time she continued to take the same medications.
  • When she visited again, CEA and CA15-3 level were reduced to within the normal range, and her multiple lung and pleural metastases were found to have almost completely disappeared upon computed tomography.
  • Exemestane is expected to be an effective agent for the treatment of hormonal receptor-positive postmenopausal woman with life-threatening advanced breast cancer.
  • [MeSH-major] Androstadienes / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Lung Neoplasms / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Female. Humans. Mucin-1 / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508449.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 107868-30-4 / exemestane
  •  go-up   go-down


11. Halász L, Szentkereszty Z, Furka A, Kiss S, Kollár S: [Surgical treatment of pleural metastases in breast cancer]. Magy Seb; 2002 Aug;55(4):265-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pleural metastases in breast cancer].
  • Pleural metastases of breast cancer is a severe progression of the disease and the treatment is difficult.
  • Distant metastases are mainly treated by chemo-, radio- or hormone therapy, but in recent years surgical intervention is increasingly important.
  • Between the 1st of January 1992 and 31st of December 2001 in the 2nd Department of Surgery University of Debrecen Medical and Health Science Center Medical School of Medicine 43 patients with breast cancer were operated on because of pleural metastases.
  • The surgical treatment was followed by chemotherapy.
  • Based on literature data and own experience we conclude that surgical intervention with adjuvant therapy extends life expectancy for patients with pleural metastases.
  • Pleurodesis can prevent or delay hydrothorax, it improves vital functions and the quality of life for patients with pleural metastases.
  • [MeSH-major] Breast Neoplasms / pathology. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Pleurodesis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12236084.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Klee H, Vestring T, Bittmann I: [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy]. Pneumologie; 2008 Oct;62(10):607-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy].
  • [Transliterated title] Pleurales Rezidiv eines typischen pulmonalen Karzinoids 7 Jahre nach Operation.
  • BACKGROUND: Bronchial carcinoids are a rare differential diagnosis of solitary pulmonary nodes.
  • Typically metastases develop in the lung, liver, brain, bone and adrenal glands.
  • CASE REPORT: Seven years after lobectomy of a bronchial carcinoid, a slow-growing thickening of the pleura parietalis was noted in a 54-year-old male patient.
  • The histological diagnosis of pleural metastases was established via trans-thoracic punctation.
  • Pleural metastases of bronchial carcinoids are extremely rare.
  • Palliative cytotoxic chemotherapy was started.
  • Metastatic disease--as in the rare case of pleural metastases shown here--remains a therapeutic dilemma.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711695.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Mambrini A, Fiorentini G, Pennucci C, Muttini MP, Manni A, Del Freo A, Zamagni D, Rabbi C, Sanguinetti F, Cantore M: Intra-arterial hepatic chemotherapy combined with systemic infusion of 5-FU in patients with advanced biliary tract cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):4197

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial hepatic chemotherapy combined with systemic infusion of 5-FU in patients with advanced biliary tract cancers.
  • : 4197 Background: The prognosis of advanced biliary tract cancer (ABTC) is very poor.
  • Common systemic chemotherapy (CHT) have been reported to produce transient partial remission only in a small proportion of patients (PTS).
  • 13 PTS were male; median age was 65 years (49-75); performance status was 0-1 in 17 PTS, 2 in 9 PTS; all had hystological confirmed ABTC; 21 PTS had cholangiocarcinoma and 5 PTS had gallbladder carcinoma, with liver involvement > 50% in 10 and < 50% in 16 PTS; three PTS ha peritoneal involvement, 3 had pleural metastases and 2 had bone involvement.
  • RESULTS: 125 cycles were administered, with a median of 6 cycles per patient (1-8); no side effects related to angiographic procedure were observed, while 6 cases of deep venous thrombosis related to central venous catheter occurred.
  • The overall response rate, including complete response (CR), partial response (PR) and stable disease (SD) was 21/26 (80%); 1 patient had CR, evaluated by positron emission tomography (PET), 8 PTS had PR, 12 had SD and 5 showed a progression of disease.
  • Median time to progression is 7 months (3-19).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013886.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Inoue K, Tabei T, Kusawake T, Sugamata N, Suemasu K, Higashi Y, Kurosumi M: [A case of lung and pleural metastases from breast cancer responding to toremifene]. Gan To Kagaku Ryoho; 2001 Feb;28(2):221-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung and pleural metastases from breast cancer responding to toremifene].
  • A patient with lung and pleural metastases from breast cancer treated effectively with toremifene is reported.
  • A 62-year-old woman underwent mastectomy for breast cancer, and had high levels of estrogen and progesterone receptor.
  • After 2-years of adjuvant UFT therapy, lung and pleural metastases were seen on a chest x-ray.
  • After five months with toremifene, a chest x-ray and CT scan showed the disappearance of lung and pleural metastases.
  • No recurrence or metastases have been detected for twenty months to date.
  • High-dose toremifene might be an effective therapy for cases of postmenopausal metastatic breast cancer, with high levels of estrogen and progesterone receptor.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Selective Estrogen Receptor Modulators / therapeutic use. Toremifene / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242650.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Selective Estrogen Receptor Modulators; 7NFE54O27T / Toremifene
  •  go-up   go-down


15. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • We report the 9th case of a gastrointestinal metastasis of osteosarcoma reported thus far, and only the second one arising in the duodenum.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Sakurai T, Oura S, Kinoshita T, Yokochi H, Enomoto K, Nishimura M, Okamura Y: [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. Gan To Kagaku Ryoho; 2002 Sep;29(9):1607-10
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
  • A 63-year-old postmenopausal woman was referred to our hospital for treatment of ER positive advanced breast cancer.
  • The patient had lung and pleural metastases with pleural effusion from breast cancer.
  • She was treated with anastrozole, a 3rd-generation aromatase inhibitor, which brought about a marked regression of the lung tumor, and disappearance of pleural effusion.
  • The patient experienced no adverse effects with this therapy.
  • Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Enzyme Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Nitriles / therapeutic use. Pleural Neoplasms / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Aromatase Inhibitors. Drug Administration Schedule. Female. Humans. Middle Aged. Pleural Effusion, Malignant / drug therapy. Postmenopause. Receptors, Estrogen / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12355946.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


17. Khadse P, Prabhash K, Pramesh CS, Chaturvedi P, Shet T: Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma. Diagn Cytopathol; 2009 Sep;37(9):680-5
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
  • Malignant mixed tumor of the parotid is known to have odd sites for metastases.
  • We describe the fine-needle aspiration cytology (FNAC) findings of pleural metastasis from a malignant mixed tumor misdiagnosed as a mesothelioma on cytology at the onset.A 47-year-old man presented to us with breathlessness and a massive pleural effusion with pleural-based nodules.
  • FNAC from the pleural lesions showed myxoid background substance with entrapped cuboidal epithelial cells with atypical nuclei, which were interpreted as mesothelial cells.
  • These cells in contrast to the usual mesothelial cells were not arranged in sheets but rather were huddled in places and formed a pseudoacinar pattern and blended with the myxoid substance.After the diagnosis of a mesothelioma, patient received pemetrexed and cisplatin based chemotherapy with partial response.
  • While on chemotherapy tumor recurred at the primary site in parotid and was confirmed to be a carcinosarcoma on a FNAC and biopsy.To conclude, pleural metastases from a true malignant mixed tumor of the parotid gland can be misdiagnosed as mesothelioma and could occur in the absence of uncontrolled disease at primary site.
  • Both mesotheliomas and pleomorphic adenomas metastatic to the pleura are biphasic tumors, but in a patient with history of pleomorphic adenoma, the latter should be kept as a foremost possibility.
  • Attention to the cytomorphology of tumor cells will also assist in confirming the diagnosis.
  • [MeSH-major] Carcinosarcoma / secondary. Mesothelioma / pathology. Neoplasms, Complex and Mixed / secondary. Parotid Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Diagnosis, Differential. Diagnostic Errors. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pemetrexed. Pleural Effusion, Malignant / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373913.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Mori T, Yoshioka M, Iwatani K, Kobayashi H, Yoshimoto K, Nomori H: Kissing pleural metastases from metastatic osteosarcoma of the lung. Ann Thorac Cardiovasc Surg; 2006 Apr;12(2):129-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kissing pleural metastases from metastatic osteosarcoma of the lung.
  • Two patients with osteosarcoma lung metastases of which migrated to the parietal pleura due to contact are reported.
  • The first patient was a 16-year-old male who had a pleural metastasis in the diaphragm within an area in contact with a single lung metastasis.
  • Both of the tumors were resected, followed by systemic chemotherapy.
  • Nine months after the resection of the first metastases, two other lung metastases were found which were resected after chemotherapy.
  • The patient is alive without recurrence 84 months after the first resection of the metastases.
  • The second patient was an 11-year-old female with a pleural metastasis of osteosarcoma which was within an area in contact with a single lung metastasis, which had been resected 4 months before.
  • We concluded (1) that a lung metastasis of osteosarcoma occasionally metastasizes to the pleura due to contact; and (2) that because this kissing metastases of osteosarcoma could be cured by a complete resection, the intrathoracic cavity should be thoroughly observed.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / secondary. Osteosarcoma / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Female. Femur / pathology. Humans. Male. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702936.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Dy Echo AV, Soriano-Estrella AS: Gestational trophoblastic tumor in pregnancy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):875-81
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic tumor in pregnancy: a case report and review of the literature.
  • A case of gestational trophoblastic tumor (GTT) concurrent with an intrauterine pregnancy is reported in a 21-year-old gravida 2 para 0 (0010) who presented with dyspnea, orthopnea, headache, and blurring of vision at 33 weeks age of gestation.
  • Chest radiograph showed pulmonary metastases, with pleural effusion on both lungs.
  • Due to worsening maternal pulmonary condition, the patient underwent primary, low segment cesarean section and was subsequently started on multidrug chemotherapy.
  • Several hypotheses regarding its origin, its diagnosis, and its management and prognosis are presented.
  • This case report emphasizes the importance of early diagnosis and treatment to improve the prognosis of both the mother and the infant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Chlorambucil / therapeutic use. Dactinomycin / therapeutic use. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Methotrexate / therapeutic use. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681776.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate; MDC protocol
  •  go-up   go-down


20. Kunitomo K, Inoue S, Ichihara F, Kono K, Fujii H, Matsumoto Y, Ooi A: A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol; 2004 Mar;35(3):379-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
  • A 38-year-old woman with cancer of the left breast underwent a modified radical mastectomy with lymph node dissection.
  • Twenty-one months later, massive liver metastases and pleural carcinomatosis occurred.
  • The liver metastases responded completely to chemotherapy with trastuzumab combined with docetaxel, but the pleural carcinomatosis was refractory to the therapy.
  • Fluorescence in situ hybridization showed that both the primary tumor and the metastatic tumors of the lymph nodes were composed of HER2 amplification-positive and HER2 amplification-negative cancer cells.
  • This analysis also detected a single cell with HER2 amplification in the pleural effusion that was taken at the completion of the chemotherapy, but four follow-up tests showed no amplified cells.
  • It is speculated that in the liver metastases, the trastuzumab was cytotoxic to both HER2-amplified and nonamplified cancer cells and may have acted through its antiangiogenic effect.
  • However, in the pleural effusion, the effect of trastuzumab was more specific to HER2-amplified cells and caused outgrowth of cancer cells lacking expression of HER2 receptors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / therapeutic use. Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Taxoids / administration & dosage. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017597.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


21. Graeber GM, Tamim W: Current status of the diagnosis and treatment of thymoma. Semin Thorac Cardiovasc Surg; 2000 Oct;12(4):268-77
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of the diagnosis and treatment of thymoma.
  • Although thymomas are rare neoplasms, they are the most common tumor of the anterior mediastinum in adults.
  • Preferred therapy for these neoplasms is complete surgical resection.
  • If a thymoma cannot be completely resected, postoperative radiotherapy may produce satisfactory results in controlling the tumor.
  • Significant 5- and 10-year survival rates have been recorded for patients with advanced thymomas who have been treated by radiation therapy alone.
  • Chemotherapy may be used in patients with unresectable thymomas as well, but the results are less promising than with radiotherapy.
  • Combinations of radiotherapy and chemotherapy used on patients with unresectable thymomas have produced encouraging results.
  • Surveillance of patients with thymoma should be prolonged because late recurrence (more than 5 years after initial therapy) can be expected in a significant minority of patients.
  • Aggressive therapy of late recurrence, including resection of new tumor masses and pleural metastases, has yielded successive disease-free intervals that validate persistent treatment.
  • [MeSH-minor] Humans. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11154722.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 53
  •  go-up   go-down


22. Rachid H, El Biaze M, Yassine N, Loudadsi F, Bakhatar A, Alaoui-Yazidi A, El Meziane A, Bahlaoui A: [Mediastinal paraganglioma with pleural metastasis. A case report]. Rev Pneumol Clin; 2005 Oct;61(5 Pt 1):315-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal paraganglioma with pleural metastasis. A case report].
  • Paraganglioma is rare tumor arising from chromaffine cells.
  • Computed tomography (CT) revealed a solid mass in the anterior mediastinum.
  • Surgical removal of this vascularized and invasive tumor was not possible to.
  • Three years later, the patient developed chest pain.
  • CT findings showed right nodular pleural masses.
  • Chemotherapy was proposed without significant response.
  • This observation confirmed the rare course of paraganglioma to pleural metastases.
  • Treatment of paraganglioma is mainly surgery if the mass is resectable.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Paraganglioma / secondary. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292158.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Homsi J, Walsh D, Nelson KA, Sarhill N, Rybicki L, Legrand SB, Davis MP: A phase II study of hydrocodone for cough in advanced cancer. Am J Hosp Palliat Care; 2002 Jan-Feb;19(1):49-56
Hazardous Substances Data Bank. HYDROCODONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of hydrocodone for cough in advanced cancer.
  • PURPOSE: Cough is a common symptom in advanced cancer.
  • This study evaluates hydrocodone for cough in advanced cancer METHODS: The results presented are from a phase II study with dose titration.
  • Nine patients had lung cancer and seven had lung or pleura metastases; 19 patients had at least 50 percent improvement of their cough frequency.
  • CONCLUSIONS: Hydrocodone is effective and safe to treat cough in advanced cancer A starting dose of 10 mg per day in divided doses seems effective.
  • [MeSH-major] Antitussive Agents / therapeutic use. Cough / drug therapy. Hydrocodone / therapeutic use. Lung Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Palliative Care. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Cold and Cough Medicines.
  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171425.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitussive Agents; 6YKS4Y3WQ7 / Hydrocodone
  •  go-up   go-down


24. Jimenez RE, Folpe AL, Lapham RL, Ro JY, O'Shea PA, Weiss SW, Amin MB: Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases. Am J Surg Pathol; 2002 Mar;26(3):320-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases.
  • Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) is an extraordinarily rare primary tumor in the kidney and can be mistaken for a variety of other round cell tumors, including blastema-predominant Wilms' tumor (WT).
  • Immunohistochemistry for the carboxy-terminus of FLI-1 is sensitive and highly specific for the diagnosis of ES/PNET.
  • WT-1, the WT-associated tumor suppressor gene, is overexpressed in WT but not in ES/PNET.
  • The mean tumor size was 11.8 +/- 3.8 cm (mean +/- standard deviation).
  • Follow-up on 8 cases (mean, 28 mo; range, 6-64 mo) showed 4 lung and pleural metastases, 1 bone metastasis, liver metastasis, 2 local recurrences, and 5 deaths from disease (median time to death, 16.8 mo).
  • No case had distant metastatic disease at presentation.
  • Adjuvant therapy included chemotherapy (8 cases), radiation (3 cases), and bone marrow transplantation (1 case).
  • Our study affirms a unique proclivity of renal ES/PNET for young adults and that it is a highly aggressive neoplasm, with rapid death in many cases, usually after the development of treatment-resistant lung metastases.
  • These tumors must be distinguished from blastema-predominant WT and other primitive renal tumors that require different therapy.
  • FLI-1 and WT-1 immunohistochemistry may be valuable in this differential diagnosis, given the known immunophenotypic overlap between ES/PNET and blastema-predominant WT with regard to CD99, cytokeratin, and desmin.
  • The accurate distinction between these two entities has clear prognostic and therapeutic implications.
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Child. Combined Modality Therapy. DNA-Binding Proteins / analysis. Desmin / analysis. Diagnosis, Differential. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neoplasm Metastasis. Proto-Oncogene Protein c-fli-1. Trans-Activators / analysis. WT1 Proteins / analysis. Wilms Tumor / chemistry. Wilms Tumor / genetics. Wilms Tumor / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2003 Aug;27(8):1177 [12883255.001]
  • (PMID = 11859203.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / DNA-Binding Proteins; 0 / Desmin; 0 / Proto-Oncogene Protein c-fli-1; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / WT1 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


25. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Metastatic monophasic synovial sarcoma of the pleura. Ann Thorac Cardiovasc Surg; 2007 Aug;13(4):258-61
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic monophasic synovial sarcoma of the pleura.
  • Pleural metastasis of synovial sarcoma that originally developed in the soft tissue is a very rare entity.
  • An asymptomatic 25-year-old female, with a history of a resected synovial sarcoma in her left brachial muscle and pulmonary metastasectomy of the right lung, presented a small nodule in the periphery of the left lung on a routine chest-computed tomography.
  • A soft flat red tumor approximately 2 cm in diameter was shown on the pleura of the lingula, mimicking a blood clot on the pleura.
  • The tumor was removed by partial resection of the lung.
  • The mass lay in the pleura and did not seem to invade the lung parenchyma macroscopically.
  • Intraoperative frozen sectioning evidenced metastatic synovial sarcoma.
  • Many small patchy red lesions were also found on the visceral pleura of the lung and parietal pleura of the diaphragm.
  • We diagnosed unresectable pleural metastases of synovial sarcoma and finished the operation after sampling another pulmonary pleural lesion.
  • The patient then underwent ifomide-based chemotherapy and survived for 3 years after her initial surgery.
  • Postoperative histopathological examination revealed a solid and bundle-like proliferation of a short spindle cell tumor with a monophasic pattern, which was diagnosed as a metastatic pleural synovial sarcoma.
  • [MeSH-major] Muscle Neoplasms / pathology. Pleural Neoplasms / secondary. Sarcoma, Synovial / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717503.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Massone PP, Lequaglie C, Macnani B, Conti B, Cataldo I: [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms]. Chir Ital; 2001 May-Jun;53(3):291-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms].
  • [Transliterated title] L'importanza della chirurgia toracoscopica video-assistita nella diagnostica e nella stadiazione delle neoplasie polmonari primitive.
  • The authors describe the usefulness of video-assisted thoracoscopic surgery (VATS) in the staging and diagnosis of primary lung cancer.
  • In the Oncological Thoracic Surgery Department of Milan's National Cancer Institute, over the period from January 1995 to January 2000, 46 patients, suspected of having mediastinal lymphadenopathies in the presence of lung cancer, were proposed for a VATS biopsy.
  • Forty-four patients underwent a thoracoscopic lymph node biopsy (95%), while in 2 subjects, in whom pleural metastases were found, the histological diagnosis was established by pleural metastatic nodule thoracoscopic biopsy (5%).
  • The subsequent treatment was neoadjuvant chemotherapy for stage III A patients and chemotherapy in association with radiotherapy for stage III B subjects.
  • The patients with microcytoma underwent integrated radiotherapy and chemotherapy and pan-encephalic radiotherapy.
  • In conclusion, VATS proved extremely useful in the diagnosis and staging of patients affected by lung cancer with synchronous lymph node enlargement.
  • This procedure allowed the diagnosis of suspect involved mediastinal lymph nodes in all cases thus affected and the exclusion of lymph node disease in patients subsequently treated by lung resection in a single session.
  • The precise staging obtained then made it possible to direct the patients towards the most appropriate form of treatment.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452813.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Maruyama S, Ito M, Hirano Y, Shimo T, Hashida S, Iga K, Inukai M, Kanaya Y, Yokoyama N: [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1787-9
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
  • A 51-year-old postmenopausal woman was referred to our hospital for treatment of ER-positive recurrent breast cancer.
  • The patient had lung and pleural metastases with pleural effusion from breast cancer.
  • The efficacy of the treatment was definite: the multiple metastatic lung lesions showed a partial response after 5 months' treatment, and reached a complete response after 14 months' treatment.
  • The patient experienced no adverse effects with this therapy.
  • Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931590.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


28. Kurdow R, Boehle AS, Haye S, Boenicke L, Schniewind B, Dohrmann P, Kalthoff H: Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer. Ann Thorac Surg; 2002 Mar;73(3):905-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer.
  • BACKGROUND: Therapy failures have been reported for retroviral gene transfer of herpes simplex virus thymidine kinase (HSV-TK) gene followed by systemic ganciclovir application in human lung cancer.
  • Use of the HSV-TK mutant TK30 in combination with a VSV-G pseudotyped retroviral vector was found to enhance the efficacy of prodrug therapy.
  • The present study evaluated this therapeutic strategy in human non-small cell lung cancer cell lines in a preclinical murine xenotransplant model.
  • METHODS: Intrathoracally induced by HSV-TK30 transduced non-small cell lung cancer cell lines Colo 699 (adenocarcinoma) and KNS 62 (squamous cell carcinoma) were monitored for local tumor growth, survival, and metastases.
  • RESULTS: Survival was significantly prolonged, and tumor growth and pleural metastases were reduced in HSV-TK30-positive tumors of both cell lines.
  • A significant therapeutic effect in bystander experiments was observed in squamous cell carcinoma.
  • CONCLUSIONS: Delivery of HSV-TK30 in a VSV-G pseudotyped retroviral vector and subsequent ganciclovir application provided therapeutic efficacy.
  • Despite of low transduction rates achievable in gene transfer in situ, prodrug therapy appears to be feasible in tumor cells with efficient bystander effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antiviral Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ganciclovir / therapeutic use. Genetic Vectors. Lung Neoplasms / drug therapy. Prodrugs. Thymidine Kinase / genetics
  • [MeSH-minor] Animals. Connexin 43 / metabolism. Disease Models, Animal. Female. Herpes Simplex / enzymology. Humans. Mice. Mice, SCID. Neoplasm Transplantation. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2002 Mar;73(3):704-6 [11899169.001]
  • (PMID = 11899199.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Connexin 43; 0 / Prodrugs; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


29. Kokufu I, Tanei T, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K, Tamaoka K, Hosono M: [Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer]. Gan To Kagaku Ryoho; 2003 Jan;30(1):111-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer].
  • We report two cases in which weekly paclitaxel (TXL) administration and concurrent radiation was effective for metastatic breast cancer.
  • Case 1: A 50-year-old woman was found to have atelectasis of the middle lobe after treatment for brain metastasis.
  • She was diagnosed with hilar, mediastinal and supraclavicular lymph nodes metastases.
  • The metastatic lymph nodes had disappeared one month after the treatment.
  • Case 2: A 31-year-old woman was diagnosed with advanced breast cancer with lung, pleural, bone and orbital metastases.
  • The lung and pleural metastases had disappeared and the orbital metastasis was decreased by 75% one month after the treatment, and the case was assessed as a partial response.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12557714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Pacheco-Ojeda LA, Martínez AL, Alvarez M: Anaplastic thyroid carcinoma in ecuador: analysis of prognostic factors. Int Surg; 2001 Apr-Jun;86(2):117-21
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this country, ATC is the third most common histologic type of thyroid cancer, following papillary and follicular carcinoma.
  • The aim of this study was to review the clinical presentation and the results of treatment of a large consecutive series of ATC patients treated at the oncological department of a general hospital in Quito, Ecuador.
  • All the patients had histological diagnosis of ATC.
  • Two patients with pulmonary metastases and pleural effusion died before treatment could be instituted.
  • Twenty-eight patients received at least one type of treatment: surgery, radiation therapy (RT), or chemotherapy (CT).
  • The two most frequently employed therapeutic modalities were surgery followed by RT and/or CT in 14 patients and surgery alone in 9 patients.
  • The prognostic value of the following parameters was studied by univariate analysis: duration of symptoms, size of the tumor, extent of glandular involvement, type of treatment, and surgical margins.
  • A statistically longer survival was found in cases of differentiated carcinoma with areas of ATC or tumor limited to one lobe, those patients who received a complete treatment of chemotherapy, and those patients with tumors smaller than 10 cm and with duration of symptoms longer than 4 months.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Ecuador / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11918236.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Cohen-Mouly S, Badia A, Bats AS, Barthes F, Bensaïd C, Riquet M, Lécuru F: Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int J Gynecol Cancer; 2009 Dec;19(9):1662-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion.
  • OBJECTIVES: To evaluate the feasibility of video-assisted thoracoscopy (VAT) for staging advanced ovarian cancer, to measure the performance of preoperative computed tomography (CT) for diagnosing pleural metastases, to assess the correlation between pleural and abdominal involvement, and to measure the impact of VAT on patient management.
  • METHODS: We retrospectively evaluated 16 VAT procedures in 15 patients with advanced ovarian malignancies and pleural effusions.
  • The reason for VAT was either to evaluate unilateral or bilateral pleural effusions (n = 15) or to evaluate pleural metastases after neoadjuvant chemotherapy (n = 1).
  • The rates of involvement of the hepatic pedicle, mesentery, and right side of the diaphragm were compared with the rate of pleural involvement.
  • RESULTS: The right side of the chest was examined 12 times; and the left side, 4 times.
  • There were no complications; 1 procedure was stopped because of ventilatory intolerance.
  • Video-assisted thoracoscopy identified metastases smaller than 1 cm in 5 patients and larger than 1 cm in 2 additional patients; there was no evidence of pleural involvement in 6 patients.
  • Computed tomography had 14% sensitivity and 25% specificity for pleural status determination, using VAT biopsy as the reference standard.
  • Pleural involvement did not correlate with involvement of the hepatic pedicle, mesentery, or right side of the diaphragm.
  • CONCLUSIONS: Video-assisted thoracoscopy performs better than CT for evaluating pleural involvement in ovarian cancer.
  • [MeSH-major] Carcinoma / surgery. Ovarian Neoplasms / surgery. Pleural Effusion, Malignant / diagnosis. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Biopsy, Needle. Disease Progression. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955956.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Okereke IC, Kesler KA, Morad MH, Mi D, Rieger KM, Birdas TJ, Badve S, Henley JD, Turrentine MW, Nelson RP, Loehrer PJ: Prognostic indicators after surgery for thymoma. Ann Thorac Surg; 2010 Apr;89(4):1071-7; discussion 1077-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve of these patients were determined to have either World Health Organization type C disease or Masaoka stage IV-B disease and were excluded from analysis.
  • Thirteen of the 28 (46.2%) patients who presented with stage III or IV-A disease received preoperative chemotherapy.
  • CONCLUSIONS: Long-term disease-specific survival can be expected not only after surgery for early stage thymoma but also after surgery for advanced disease, including patients with pleural metastases.
  • Late mortality due to secondary cancers and associated immunologic disorders was more frequent than mortality from thymoma in this series.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20338309.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Kurdow R, Boehle AS, Ruhnke M, Mendoza R, Boenicke L, Sipos B, Schniewind B, Dohrmann P, Kalthoff H: Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model. Langenbecks Arch Surg; 2003 Dec;388(6):401-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model.
  • BACKGROUND AND AIMS: The administration of endostatin, a potent anti-angiogenic agent, will be required for extended periods of time as a cancer treatment.
  • The tumor response was evaluated in an orthotopic murine tumor model of human lung cancer.
  • MATERIALS AND METHODS: Human non-small-cell lung cancer cells (KNS 62) were retrovirally transduced with the human endostatin gene.
  • An orthotopic murine xenotransplant model was used to investigate tumor growth, metastases and survival.
  • After 4 weeks of subcutaneous growth, endostatin expression was measured by immunoblot analysis in tumor lysates.
  • RESULTS: The growth of the subcutaneous tumors was significantly delayed, and orthotopic tumor growth and pleural metastases were significantly reduced in endostatin-transduced KNS 62 tumors.
  • Prolongation of survival subsequent to orthotopic tumor induction was demonstrated.
  • Endostatin transduction provides significant anti-tumor effects with regard to local tumor growth, metastases and survival.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Endostatins / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Animals. Female. Gene Transfer Techniques. Humans. Immunoblotting. Mice. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Gene Ther. 2001 Jan;8(1):45-54 [11219493.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):420-8 [11745424.001]
  • [Cites] Ann Thorac Surg. 2000 Apr;69(4):1010-5 [10800785.001]
  • [Cites] J Cell Biol. 2002 Aug 5;158(3):529-39 [12147676.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27872-9 [12029087.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):526-31 [11212245.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):343-8 [10207881.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Blood. 1994 Jan 1;83(1):43-50 [8274751.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] BMC Cancer. 2002 Jul 29;2:17 [12147175.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6251-6 [10626820.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3308-12 [10416583.001]
  • [Cites] Hum Gene Ther. 2001 Mar 1;12(4):347-58 [11242527.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5673-7 [9865720.001]
  • [Cites] Gene Ther. 2002 Jul;9(13):867-78 [12080381.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):835-9 [11275988.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1503-6 [10749112.001]
  • [Cites] FEBS Lett. 2002 May 22;519(1-3):147-52 [12023034.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 12898260.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endostatins
  •  go-up   go-down


34. de Bree E, van Ruth S, Rutgers EJ, Zoetmulder FA: Intraoperative hyperthermic intrathoracic perfusion chemotherapy for pleural metastases of thymic neoplasms. Eur J Surg Oncol; 2002 Sep;28(6):685-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative hyperthermic intrathoracic perfusion chemotherapy for pleural metastases of thymic neoplasms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Intraoperative Care. Perfusion. Pleural Neoplasms / secondary. Pleural Neoplasms / therapy. Thymoma / pathology. Thymoma / therapy. Thymus Gland / pathology. Thymus Gland / surgery. Thymus Neoplasms / pathology. Thymus Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Surg Oncol. 2001 Nov;27(7):636-40 [11669591.001]
  • (PMID = 12374104.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down






Advertisement